Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?

Author: Doggrell S.A.

Source: Expert Opinion on Pharmacotherapy, Volume 5, Number 4, 1 April 2004 , pp. 955-958(4)

Publisher: Informa Healthcare

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

In osteoporosis, both the bisphosphonate alendronate and parathyroid hormone_(1–34) (PTH_(1–34)) have been shown to reduce the incidence of fractures. As bisphosphonates and PTH have different mechanisms, it has been proposed that their effects in osteoporosis may be additive. However, a major clinical trial of PTH_(1–84) and alendronate in postmenopausal women demonstrated that their effects were not additive. A further trial in men with osteoporosis showed that alendronate impaired the ability of PTH_(1–34) to increase bone mineral density. The combination of alendronate and PTH does not have greater benefit than either agent alone, and may even be detrimental, thus should not be used.

Keywords: alendronate; bone mineral density; clinical trial; osteoporosis; parathyroid hormone

Document Type: Miscellaneous

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$99.00 plus tax Refund Policy